Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis

By sjmartinez • July 16, 2024

Paik JJ, Vencovský J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, Mudd PN Jr, Aggarwal R. Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2024 Jul 15. doi: 10.55563/clinexprheumatol/eeglsa. Epub ahead of print. PMID: 39008325.

Tags: Publications, Rheumatology

Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan[...]

Pulmonary Rehabilitation Referral Practice Patterns Across Lung Transplantation Centers in the United States: A Multicenter Survey-Based Study

Deleija JD, Shah SZ, Felzer J, Tan X, Garvey C, DeCato TW, Pennington K, Sehgal S, Kennedy C, Kumar A. Pulmonary Rehabilitation Referral Practice Patterns[...]

Cardiovascular Outcomes in Patients With Cancer Undergoing Cardiac Implantable Electronic Device Implantation

Krishan S, Agarwal S, Munir MB, Ajijola O, Yang EH, Deswal A, Torbey E, Cheng R, Asad ZUA. Cardiovascular Outcomes in Patients With Cancer Undergoing[...]